Plain-English translation of NCT06925542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of immunotherapy made from healthy donor immune cells that have been genetically modified using CRISPR gene-editing technology. The treatment is designed to help people with severe autoimmune diseases like lupus, systemic sclerosis, or inflammatory myopathy that have not improved with standard medications. Researchers want to learn whether this medication is safe and whether it can reduce disease activity in patients who have run out of other options.
Some people with autoimmune diseases do not respond well enough to existing treatments, and their conditions continue to cause serious damage. This trial exists to test whether a completely new approach—using genetically engineered immune cells—might help patients whose disease has proven difficult to control.
You likely qualify if…
You likely don't qualify if…
Participants will receive a chemotherapy regimen to prepare their immune system, followed by a single infusion of the genetically modified cells through an IV. You will then be monitored closely with frequent visits and blood tests over several months to watch for safety concerns and signs that the treatment is working. The study involves regular follow-up appointments and careful tracking of your disease activity and any side effects.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States